모세혈관 채혈 기기 시장 규모, 점유율, 동향 분석 보고서 : 재질별, 제품별, 최종 용도별, 용도별, 지역별, 부문별 예측(2025-2030년)

Capillary Blood Collection Devices Market Growth & Trends:

The global capillary blood collection devices market size is expected to reach USD 3.52 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of chronic, infectious, and autoimmune diseases are some of the major factors propelling market growth owing to the rising number of blood tests globally. Capillary blood draw technique has been most widely used for glucose and hemoglobin testing in clinics and hospitals. Ease of usage and minimally invasive nature also makes it ideal for home care diagnosis and testing, thereby boosting the market's growth potential. The use of this technique in conjugation with PoC diagnostics has become the chosen mode of testing in remote and ambulatory health settings.

Blood gas detection, leukocyte & metabolite count, biomarker, nucleic acid, blood glucose, ferritin, lactate, effect of vitamin K-antagonist, and heavy metal ions analysis is commonly done using these samples. Thus, with the rising adoption of rapid PoC diagnostics, the usage of these devices is anticipated to increase in the near future.

Chronic diseases are a global healthcare problem with over half of the adult population in the U.S. suffering from chronic diseases, which contribute to over 75% of the total healthcare cost in the nation. Thus, the rising number of infectious and chronic diseases creates a huge demand for diagnostic testing, thereby propelling the growth of these collection devices.

Capillary blood draw technique is most often used in the case of pediatric patients as it is difficult to draw venous and arterial blood from infants. Capillary blood draw is preferred in many ICU settings as patients lose a large amount of blood during surgeries. Other blood drawing techniques are more invasive and might result in delays in the healing process or pose a risk of contamination. Ease of usage and effectiveness is another factor facilitating the use of these devices for home care diagnosis and testing, typically in case of diabetics.

Capillary Blood Collection Devices Market Report Highlights:

• The plastic segment accounted for the largest market share of 40.6 % in 2024. The widespread adoption of plastic-based devices can be attributed to their ease of use, disposability, and cost-effectiveness.
• The glass segment is likely to grow at a CAGR of 8.9% over the forecast period. Compared to plastic, glass offers the advantage of being easily recyclable, enhancing its environmental sustainability.
• The hospitals and clinics segment captured the highest market share of 29.6% in 2024. This trend is driven by the frequent need for diagnostic testing and the large patient influx in healthcare facilities.
• The whole blood tests segment held the largest revenue share of 24.6% in 2024. Complete blood count (CBC) tests are the most commonly performed blood tests, used to measure components such as white blood cells (WBCs), red blood cells (RBCs), hemoglobin, hematocrit, and platelets.
• The lancet accounted for the largest revenue share of 33.5% in 2024. The growing demand for lancets can be attributed to their frequent use in blood draw procedures, particularly for monitoring blood glucose levels in individuals with diabetes and collecting small blood samples for at-home testing.
• The North America capillary blood collection devices market dominated and accounted for a 33.6% share in 2024. The growth is driven by a robust healthcare infrastructure and the presence of prominent clinical diagnostics companies.
• The Asia Pacific capillary blood collection devices market is expected to experience the highest growth rate of 10.0% CAGR during the forecast period owing to the increasing prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular diseases.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Material
  • 1.2.3. Application
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Material outlook
  • 2.2.3. End use outlook
  • 2.2.4. Application outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Capillary Blood Collection Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Demand for Point-of-Care Testing
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Increased Prevalence of Chronic Diseases
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited Sample Volume
    • 3.2.2.2. Lack of Standardization
• 3.3. Capillary Blood Collection Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Capillary Blood Collection Devices Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Capillary Blood Collection Devices Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Lancets
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.2. Micro-Container Tubes
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Micro-Hematocrit Tubes
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Warming Devices
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Capillary Blood Collection Devices Market: Material Estimates & Trend Analysis

• 5.1. Material Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Capillary Blood Collection Devices Market by Material Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Plastic
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 5.4.2. Glass
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Stainless steel
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Ceramic
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.5. Others
    • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Capillary Blood Collection Devices Market: End Use Estimates & Trend Analysis

• 6.1. End Use Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Capillary Blood Collection Devices Market by End Use Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Hospitals and Clinics
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.4.2. Blood Donation Centers
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Diagnostic Centers
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Home Diagnosis
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Pathology Laboratories
    • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Capillary Blood Collection Devices Market: Application Estimates & Trend Analysis

• 7.1. Application Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Capillary Blood Collection Devices Market by Application Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Whole Blood
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.4.2. Plasma/Serum Protein Tests
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Comprehensive Metabolic Panel Tests
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Liver Panel/ Liver Profile/ Liver Function Tests
    • 7.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Dried Blood Spot Tests
    • 7.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Capillary Blood Collection Devices Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.1.5. )
  • 8.8.2. Argentina
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. Key company market share analysis, 2024
  • 9.3.2. Becton, Dickinson and Company
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Product benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Greiner Bio-One International GmbH
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Product benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. SARSTEDT AG & Co. KG
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Terumo Medical Corp
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. B. Braun Melsungen AG
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Improve Medical
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. Abbott Laboratories
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Cardinal Health
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Rhinostics
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. Biodesix
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives